Table 1 Clinicopathological characteristics of the melanoma cohort treated with anti-PD-1 therapy and the control melanoma cohort for CAF profiling
Characteristic | Anti-PD-1 patients, No. (%) | Objective response rate (CR/PR), No. (%) | Disease control rate (CR/PR/SD), No. (%) | Control patients, No. (%) |
|---|---|---|---|---|
Overall | 117 (100) | 55 (47) | 81 (69) | 194 (100) |
Age (y) | ||||
 < 65 | 67 (57) | 34 (51) | 51 (76) | 87 (45) |
 ≥ 65 | 50 (43) | 21 (42) | 30 (60) | 107 (55) |
Sex | ||||
 Male | 70 (60) | 35 (50) | 48 (69) | 110 (57) |
 Female | 47 (40) | 20 (43) | 33 (70) | 84 (43) |
Treatment | ||||
 Pembrolizumab | 41 (35) | 20 (49) | 30 (73) | 0 |
 Nivolumab | 18 (15) | 7 (39) | 9 (50) | 0 |
 Ipilimumab plus nivolumab | 58 (50) | 28 (48) | 42 (72) | 0 |
Prior immune checkpoint blockade | ||||
 Yes | 36 (31) | 13 (36) | 22 (61) | 0 |
 No | 81 (69) | 42 (52) | 59 (73) | 194 (100) |
Mutation status | ||||
 BRAF | 39 (33) | 19 (49) | 27 (69) | NA |
 NRAS | 18 (15) | 8 (44) | 11 (61) | NA |
 KIT | 2 (2) | 1 (50) | 2 (100) | NA |
 None detected | 58 (50) | 27 (47) | 41 (71) | NA |
Stage at diagnosis | ||||
 I | 24 (21) | 14 (58) | 19 (79) | 77 (40) |
 II | 23 (20) | 12 (52) | 16 (70) | 80 (41) |
 III | 38 (32) | 16 (42) | 24 (63) | 30 (15) |
 IV | 20 (17) | 6 (30) | 13 (65) | 3 (2) |
 Not available | 12 (10) | 7 (58) | 9 (75) | 4 (2) |